Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly NNC0519-0130 in type 2 diabetes – phase 2 dose-finding study
jRCT2031230704Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2024
- Modality
- Small Molecules, Peptides
01
Overview
Phase 2, randomised, double-blind trial of NNC0519-0130 in type 2 diabetes mellitus (T2DM) (11 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c at week 12 on maintenance dose. Started Mar 2024; status: completed.
02
Drugs
NNC0519-0130
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031230704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230704.